BOLT - Bolt Biotherapeutics, Inc.

4.99
-0.160   -3.206%

Share volume: 14,439
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$5.15
-0.16
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 30%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
5.50%
1 Month
13.93%
3 Months
-20.16%
6 Months
-11.05%
1 Year
1,282.27%
2 Year
984.78%
Key data
Stock price
$4.99
P/E Ratio 
N/A
DAY RANGE
$4.77 - $5.40
EPS 
-$7.97
52 WEEK RANGE
$0.26 - $7.35
52 WEEK CHANGE
$1,241.40
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
1.922 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$19,841
AVERAGE 30 VOLUME 
$19,098
Company detail
CEO: Randall C. Schatzman
Region: US
Website: boltbio.com
Employees: 90
IPO year: 2021
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Bolt Biotherapeutics, Inc. engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors.

Recent news